These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8239534)
1. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Teicher BA; Liu SD; Liu JT; Holden SA; Herman TS Anticancer Res; 1993; 13(5A):1549-56. PubMed ID: 8239534 [TBL] [Abstract][Full Text] [Related]
2. Interaction of PtCl4(Fast Black)2 with hyperthermia. Teicher BA; Herman TS; Pfeffer MR; Alvarez Sotomayor E; Khandekar VS Cancer Res; 1989 Nov; 49(22):6208-13. PubMed ID: 2804969 [TBL] [Abstract][Full Text] [Related]
3. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Kusumoto T; Holden SA; Ara G; Teicher BA Int J Hyperthermia; 1995; 11(4):575-86. PubMed ID: 7594810 [TBL] [Abstract][Full Text] [Related]
4. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo. Herman TS; Teicher BA; Coleman CN Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129 [TBL] [Abstract][Full Text] [Related]
6. Interaction of platinum complexes of thiazin and xanthene dyes with hyperthermia. Herman TS; Teicher BA; Pfeffer MR; Khandekar VS; Alvarez Sotomayor E Cancer Chemother Pharmacol; 1990; 26(2):127-34. PubMed ID: 2347038 [TBL] [Abstract][Full Text] [Related]
7. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117 [TBL] [Abstract][Full Text] [Related]
8. Interaction with hyperthermia of tetrachloroplatinum(II)(Nile blue)2 and tetrachloroplatinum(II)(neutral red)2 in EMT6 murine cells and the murine FSaIIC fibrosarcoma. Herman TS; Teicher BA; Pfeffer MR; Khandekar VS; Korbut TT Cancer Res; 1990 Jul; 50(13):3826-31. PubMed ID: 2354434 [TBL] [Abstract][Full Text] [Related]
9. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo. Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897 [TBL] [Abstract][Full Text] [Related]
10. Effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine 123(2) [tetrachloroplatinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo. Herman TS; Teicher BA; Chan V; Collins LS; Kaufmann ME; Loh C Cancer Res; 1988 May; 48(9):2335-41. PubMed ID: 3356001 [TBL] [Abstract][Full Text] [Related]
11. Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo. Teicher BA; Holden SA; Liu CJ; Ara G; Herman TS Cancer Lett; 1994 Jul; 82(1):17-25. PubMed ID: 8033065 [TBL] [Abstract][Full Text] [Related]
12. In vivo modulation of several anticancer agents by beta-carotene. Teicher BA; Schwartz JL; Holden SA; Ara G; Northey D Cancer Chemother Pharmacol; 1994; 34(3):235-41. PubMed ID: 8004757 [TBL] [Abstract][Full Text] [Related]
13. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474 [TBL] [Abstract][Full Text] [Related]
14. Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation. Teicher BA; Pfeffer MR; Alvarez Sotomayor E; Herman TS Int J Hyperthermia; 1991; 7(5):773-84. PubMed ID: 1834752 [TBL] [Abstract][Full Text] [Related]
15. CAI: effects on cytotoxic therapies in vitro and in vivo. Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563 [TBL] [Abstract][Full Text] [Related]
16. Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma. Herman TS; Teicher BA; Holden SA; Pfeffer MR; Jones SM Cancer Res; 1990 May; 50(9):2734-40. PubMed ID: 2139359 [TBL] [Abstract][Full Text] [Related]
17. Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma. Herman TS; Teicher BA Cancer Res; 1988 May; 48(10):2693-7. PubMed ID: 3359430 [TBL] [Abstract][Full Text] [Related]
18. Trimodality therapy (drug/hyperthermia/radiation) with BCNU or mitomycin C. Herman TS; Teicher BA; Holden SA Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):375-82. PubMed ID: 2105922 [TBL] [Abstract][Full Text] [Related]
19. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Kuin A; Aalders M; Lamfers M; van Zuidam DJ; Essers M; Beijnen JH; Smets LA Br J Cancer; 1999 Feb; 79(5-6):793-801. PubMed ID: 10070871 [TBL] [Abstract][Full Text] [Related]
20. Effect of environmental conditions (pH, oxygenation, and temperature) on misonidazole cytotoxicity and radiosensitization in vitro and in vivo in FSaIIC fibrosarcoma. Holden SA; Teicher BA; Herman TS Int J Radiat Oncol Biol Phys; 1991 May; 20(5):1031-8. PubMed ID: 2022503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]